Cannabis company Tilray (TLRY) is set to release its Q3 FY25 results on April 8. Tilray stock has declined over 55.5% year-to ...

Tilray Brands (NASDAQ:TLRY) shares fall for seven straight sessions, as the stock was 5.4% lower at $0.56 on Monday. The lifestyle consumer products company is scheduled to announce Q3 earnings ...

Shares of Tilray Brands Inc. TLRY shed 2.18% to $0.58 Monday, on what proved to be an all-around mixed trading session for ...

Shares of Tilray Brands were trading at $0.5922 as of April 04. Over the last 52-week period, shares are down 73.12%. Given ...

Then, in late 2020, it merged with Aphria, a major competitor. Today, Tilray is a global company selling products to countries on five continents. It sells over 40 brands of medical and adult-use ...

The facility utilizes advanced technology to manage all stages, from cultivation to packaging, ensuring high-quality cannabis products for consumers. In addition to the renowned Jean Guy ...

Shares of Tilray Brands Inc. TLRY slipped 4.16% to $0.59 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 5.82% to ...

Tilray launches Tilray Craft in Germany, offering high-THC, terpene-rich cannabis products for medical use. In a market dominated by tariff tensions, geopolitical surprises, and Fed uncertainty ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Many valuation metrics suggest that Tilray Brands (NASDAQ: TLRY) is a screaming buy right now. Just look at the cannabis stock's price-to-sales ratio. Shares traded above 2.4 times sales roughly ...

Previously cultivated in Ontario, the iconic Jean Guy strain has now found its new home in "la belle province," allowing Tilray to harness the capabilities of its high-performance facility in Québec.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.